Royal Philips (NYSE:PHG) said today that its board of directors is backing the re-appointment of Frans van Houten as its president and CEO and Abhijit Bhattacharya as chief financial officer and board member.
CEO van Houten has been at the head of Philips since 2011, while Bhattacharya joined the company in 2015, Amsterdam-based Philips said.
During his time in the corner office, van Houten led the initial public offering for Philips Lighting in May 2016 and has increased R&D investments and led acquisitions including Volcano, Spectranetics, Wellcentive and VitalHealth.
Board members will officially vote on a new CEO and CFO next May at the company’s annual general meeting of shareholders.
“The supervisory board is very pleased that Frans van Houten and Abhijit Bhattacharya remain available as members of the board of management. We recommend their re-appointment in view of the fundamental progress of Philips’ transformation into a solutions-driven health technology company with an improved growth and profitability profile. We are impressed by their continuing drive to further unlock Philips’ potential to grow its market positions and expand margins, as the company aims to make the world healthier and more sustainable through innovation,” Philips supervisory board chair Jeroen van der Veer said in a press release.
Currently, York serves as CFO to Australian company Asaleo Care. Prior to working with Asaleo Care, York acted as Cochlear‘s(ASX:COH) head of group finance and group financial controller, serving with the company for 11 years. York has also held positions with Edwards Lifesciences (NYSE:EW), Fisher & Paykel said.
“I am looking forward to joining the Fisher & Paykel Healthcare team. The company is well respected and highly successful on the global stage and I am excited to help it continue to build its reputation for sustainable growth and innovation,” York said in a press release.
York will replace long-time CFO Tony Barclay, who retired in May. Andrea Blackie will remain as acting CFO until York joins next year, the company said.
“We are delighted to welcome Lyndal to the Fisher & Paykel Healthcare team. Lyndal has strong international experience within the medical device industry, and as such, possesses a good understanding of its unique characteristics. We have a high performing and aspirational team in place and are very much looking forward to Lyndal joining us next year. I would also like to acknowledge Andrea Blackie, who has been performing the role of acting chief financial officer since 1 June 2018,” CEO & managing director Lewis Gradon said in a prepared statement.
Prior to joining Holliston, Mass.-based Harvard Biosciences, Unninayar served as CFO at clinical stage biopharmaceutical company Tetraphase. Unninayar also spent 11 years at Thermo Fisher Scientific, holding positions as finance VP for the customer channels group, laboratory products and services division and other businesses.
“Maintaining a competitive position within the global laboratory instrumentation industry requires insightful and experienced financial management. Kam Unninayar has proven herself to be an outstanding individual in this regard with a distinguished track record. Kam brings her deep knowledge of our industry, including overseeing growth strategies, operational excellence, and acquisitions while in financial leadership positions for various business segments at public companies. I look forward to partnering with Kam as we advance the company through the next phase of growth and profitability,” Barvard Bioscience CEO Jeff Duchemin said in a prepared statement.
“Harvard Bioscience has brought life science innovations to market for more than a century. I am excited to be joining during what is a transformative phase in the company’s evolution. I look forward to being a member of the executive team to help the company deliver on its strategy, accelerate its growth trajectory, and enhance value for customers and shareholders,” Unninayar said in a press release.
Prior to joining RenovaCare, Yan-Klassen has held positions with a number of accounting firms, including 5 years at BDO Canada LLP, the Scottsdale, Ariz.-based company said.
“We’re thrilled to have Steve join our roster of experienced clinical, regulatory and bioengineering professionals who have worked so hard to advance our SkinGun technology over the years. To date, over 70 patients have been experimentally treated, with many leaving the hospital in a matter of days, avoiding painful and expensive skin graft surgery. These results, along with other important factors, are why we were able to report positive outcomes from our pre-submission meeting with the U.S. FDA,” prez Thomas Bold said in a prepared release.
Sight Sciences said last week that it tapped Dr. Reay Brown, inventor of trabecular microbypass stenting, as its new chief medical officer.
Brown has published 90 peer reviewed articles on glaucoma and cataract surgery and has served as chair of the American Society of Cataract and Refractive Surgery’s glaucoma committee and as the glaucoma editor for EyeWorld magazine.
“We are extremely proud to add someone who I consider to be one of the true pioneers in the history of modern ophthalmology to our executive team. Dr. Brown’s vast experience both as a practicing surgeon and as a prolific product innovator aligns perfectly with our company’s core competencies and, on behalf of everyone at Sight Sciences, we could not be more thrilled about Dr. Brown joining the company and furthering our mission,” CEO Paul Badawi said in a press release.
“Dr. Brown has been a major force in the surgical glaucoma space for many years and he is uniquely capable of accelerating Sight Sciences’ mission to transform ophthalmology and optometry by addressing the underlying causes of the world’s more prevalent eye diseases. We’re looking forward to working closely with Dr. Brown to bring the OMNI Surgical System to cataract surgeons and glaucoma specialists around the world and to disrupt the dry eye market with TearCare, while keeping an eye on developing new products that address marketplace needs,” chief commercial officer Shawn O’Neil said in a prepared release.
“I am thrilled to join Sight Sciences as chief medical officer. I have known the leadership team for many years and have become intimately familiar with the company’s product portfolio as an active user of OMNI in my own practice. Having innovated and worked clinically within Schlemm’s canal for many years, I believe the OMNI System has tremendous potential given its unique ability to comprehensively target all three sources of resistance in the conventional outflow pathway using a single clear corneal incision. I look forward to making improvements to the existing product portfolio whenever possible, developing new products, assisting the clinical and commercial teams in the market with OMNI and TearCare, and contributing to the growing success of the company,” Brown said in prepared remarks.
- Clearside Biomedical taps Ciulla as CMO
- Bovie Medical appoints Iversen as advanced energy global ops director
- Ra Medical names Horwood as GC
- Align Tech chief marketing officer Pascaud to step away
- Crom Source names Dills as regulatory services director
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.